Molecular impact of endolysosomal dysfunction on neuron-glia communication pathways

NIH RePORTER · NIH · F32 · $74,284 · view on reporter.nih.gov ↗

Abstract

Project Abstract Alzheimer’s disease (AD) is a neurodegenerative disease and the most common form of dementia worldwide. Despite decades of research, there are few therapies that can delay or prevent AD progression. Retrograde trafficking through retromer-dependent cargo recognition has emerged as a critical cellular process that is mutated or disrupted in patients with AD and other forms of dementia. Conditional knockout of retromer genes in neurons leads to increased secretion of Tau and Amyloid β (Aβ), hallmark protein pathologies linked to AD. This milieu of neuronal-secreted factors leads to inflammation in microglia and astrocytes, two glial cell types thought to influence the progression of neurodegeneration. In this proposal, I aim to study the cascade of events linking neuronal retromer disruption to glial inflammation, characterizing the specific cell state changes involved, and identify the key factors that mediate this effect. I will address this aim using genetically engineered stem cell- derived models of human neurons, microglia, and astrocytes. Microglia also express retromer components and upregulate these factors in AD, yet there are few studies of retromer function specifically in microglia. In Aim 2 I will therefore explore the effects of retromer-related mutations specifically on microglia in the context of early aging in mice, a comparable time point to when dementia manifests in patients with these mutations. I will additionally utilize stem cell models to dissect the functional and signaling changes that are induced in microglia with retromer disruption. Finally, although there have been several studies looking at the effects of retromer on specific receptors, little is known about the systems-level effects of retromer mutations on protein trafficking to the endosomes. To identify retromer-dependent signaling pathways that may be pathogenic, I have developed novel proteomics tools to quantify endosomal proteome changes and will use these tools to compare the effects of different retromer mutations on neuronal and microglial endosomes. The ultimate goal is to understand how retromer disruption affects brain cell states and leads to pathogenic signaling changes.

Key facts

NIH application ID
10770360
Project number
5F32AG079666-02
Recipient
BOSTON CHILDREN'S HOSPITAL
Principal Investigator
Nader Francis Morshed
Activity code
F32
Funding institute
NIH
Fiscal year
2024
Award amount
$74,284
Award type
5
Project period
2023-01-29 → 2025-04-28